ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016
Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Navigating the challenges of overactive bladder management in women.World journal of urology · 2026Review
- Predictors of non-persistence in women with overactive bladder syndrome.Scientific reports · 2024Article
- Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study.Lower urinary tract symptoms · 2021Article
- Korean Translation and Linguistic Validation of Urgency and Overactive Bladder Questionnaires.International neurourology journal · 2020Article
- Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction.Investigative and clinical urology · 2020Observational
- Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care.Advances in therapy · 2019Article
- Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany.Research and reports in urology · 2019Article
- A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.BMC urology · 2018Observational
- Knowledge and attitude for overactive bladder care among women: development and measurement.BMC urology · 2018Article
- Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment.Investigative and clinical urology · 2017Article
- Translation and Linguistic Validation of the Korean Version of the "Benefit, Satisfaction, and Willingness to Continue" Questionnaire for Patients With Overactive Bladder.International neurourology journal · 2016Article
- Persistence and compliance with medication management in the treatment of overactive bladder.Investigative and clinical urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate persistence and compliance for patients receiving antimuscarinics for overactive bladder (OAB), and to assess patient-reported outcomes (PROs) according to persistence and compliance.
methodsThis was a 24-week, multicenter, prospective, observational study that included 952 OAB patients who had newly started antimuscarinics. Patients aged ≥18 years with a total OAB Symptom Score (OABSS) ≥3 and an urgency score of OABSS ≥2 were eligible for the study. Drug persistence and compliance were evaluated at 4, 12, and 24 weeks. Changes in scores on PROs were compared between groups (persistence vs. non-persistence and compliance vs. non-compliance) after 24 weeks. Factors contributing to persistence were examined using multivariate logistic regression.
resultsAfter 24 weeks, 56.8 % of patients remained on treatment. The persistence rates were 85.6 and 71.4 % after 4 and 12 weeks, respectively. The compliance rates were 75.6, 53.8, and 34.3 % after 4, 12, and 24 weeks, respectively. Patients who were persistent in taking antimuscarinics resulted in significant improvements in OABSS and OAB questionnaire short form score compared with those who were non-persistent (all p < 0.05). Changes from baseline in OABSS (p = 0.735) and the EuroQoL five-dimensions score (p = 0.384) were not significantly different between compliant and non-compliant groups. Predictors of high persistence included older age (OR 1.017, p = 0.007) and dry OAB (OR 1.422, p = 0.013).
conclusionsPatients who were persistent with antimuscarinics showed significant improvements in PROs compared to those who were non-persistent.
Indexed as
Identifiers
26701707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.